Cargando…
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world. Due to the broad heterogeneity of genetic mutations and dense stromal environment, PDAC belongs to one of the most chemoresistant cancers. Most of...
Autores principales: | Adamska, Aleksandra, Domenichini, Alice, Falasca, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535831/ https://www.ncbi.nlm.nih.gov/pubmed/28640192 http://dx.doi.org/10.3390/ijms18071338 |
Ejemplares similares
-
Current and Future Therapies for Pancreatic Ductal Adenocarcinoma
por: Sally, Áine, et al.
Publicado: (2022) -
The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
por: Parkin, Ashleigh, et al.
Publicado: (2018) -
ATP-binding cassette transporters in progression and clinical outcome of pancreatic cancer: What is the way forward?
por: Adamska, Aleksandra, et al.
Publicado: (2018) -
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)—basis and current status
por: Ramaswamy, Anant, et al.
Publicado: (2022) -
Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma
por: Sarfraz, Humaira, et al.
Publicado: (2023)